| First Author | Ikeda S | Year | 2022 |
| Journal | Sci Rep | Volume | 12 |
| Issue | 1 | Pages | 11564 |
| PubMed ID | 35798848 | Mgi Jnum | J:326548 |
| Mgi Id | MGI:7313808 | Doi | 10.1038/s41598-022-15957-2 |
| Citation | Ikeda S, et al. (2022) Smooth muscle protein 22alpha-Cre recombination in resting cardiac fibroblasts and hematopoietic precursors. Sci Rep 12(1):11564 |
| abstractText | The Cre-loxP system has been widely used for cell- or organ-specific gene manipulation, but it is important to precisely understand what kind of cells the recombination takes place in. Smooth muscle 22alpha (SM22alpha)-Cre mice have been utilized to alter genes in vascular smooth muscle cells (VSMCs), activated fibroblasts or cardiomyocytes (CMs). Moreover, previous reports indicated that SM22alpha-Cre is expressed in adipocytes, platelets or myeloid cells. However, there have been no report of whether SM22alpha-Cre recombination takes place in nonCMs in hearts. Thus, we used the double-fluorescent Cre reporter mouse in which GFP is expressed when recombination occurs. Immunofluorescence analysis demonstrated that recombination occurred in resting cardiac fibroblasts (CFs) or macrophages, as well as VSMCs and CMs. Flow cytometry showed that some CFs, resident macrophages, neutrophils, T cells, and B cells were positive for GFP. These results prompted us to analyze bone marrow cells, and we observed GFP-positive hematopoietic precursor cells (HPCs). Taken together, these results indicated that SM22alpha-Cre-mediated recombination occurs in resting CFs and hematopoietic cell lineages, including HPCs, which is a cautionary point when using SM22alpha-Cre mice. |
